Ixico surges following contract win with 'top ten' pharma giant

Ixico has inked a contract with an unnamed pharmaceutical giant to provide its technology-enabled imaging services in support of the firm's pivotal Phase III study into Huntington's disease.

The data science company told investors on Tuesday that its deal with the mystery "top ten global pharmaceutical company" had a total contract value of £9.1m, set to be delivered over a four-year term.

Ixico will work with its partner in North America, Latin America, Europe, Asia and Australasia to provide insights into brain cellular microstructure and neuronal connectivity in order to evaluate the drug's safety and efficacy.

Ixico's chief executive Giulio Cerroni, said: "This latest contract award reflects our experience working in this important area of neuroscience drug development which, together with previously announced new contracts and contract extensions, provides a strong foundation for future growth."

As of 0900 BST, Ixico shares had rocketed 38.91% to 38.20p.